N/A N=19 Neuromodulation and Yoga for Mild Traumatic Brain Injury and Chronic Pain
Mild Traumatic Brain Injury · Chronic Pain
Primary: Session Completion Rate — 60 number of sessions
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1 Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma
Astrocytoma, Grade III
Primary: Number of Participants Showing no Evidence of Disease Progression Six Months After Initiating Treatment With the Device. — 1 Participants
N/A N=25 Optimizing Cerebral Autoregulation During Surgery
Hip Fractures · Hip Arthropathy · Surgery
Primary: Mean Arterial Pressure Outside Limits of Cerebral Autoregulation — 2.2; 1.8 mmHg * hours — p=0.60
N/A N=423 The Blued+ Combination HIV Prevention Pilot Study in China
Pre-Exposure Prophylaxis
Primary: Feasibility of Blued+ in China — 193; 316 Participants
N/A N=15 Effect of Peripheral Neuromodulation on Vaginal Blood Flow - Study 2
Female Sexual Dysfunction · Female Sexual Dysfunction Due to Physical Condition
Primary: Maximum Percent Change in Vaginal Pulse Amplitude (VPA) From the Average Baseline Value — 119.8; 94.3; 135.4; 113.5 percent change of VPA
Phase 2 N=124 A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines
Forehead Lines
Primary: Number of Participants With Adverse Events — 10; 12; 18; 13 Participants
Phase 2 N=78 Effect of Antihistamines on Ureteral Stent-Related Symptoms
Nephrolithiasis
Primary: USSQ Urinary Symptom Score — 28; 29; 16; 17 score on a scale
N/A N=20 Amplifying Sensation in Underactive Bladder
Urinary Bladder, Underactive
Primary: Voiding Efficiency — 32; 53; 43; 46 voided percentage — p=1
N/A N=23 Pre-Study of Wild Type Enterotoxigenic E. Coli (ETEC) Strain for Verification of a Planned Challenge Dose
ETEC Diarrhea
Primary: Number of Participants With Moderate and Severe Diarrhea — 17 participants moderate or severe diarrea
Phase 1 N=22 Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+
Safety · Tolerability · Ocular Surface
Primary: Incidence of Related Unexpected Adverse Events (AE) — 12 Number of unexpected related AE
N/A N=13 PureWick™ France and U.S. At-Home Pilot Study
Nocturnal Enuresis
Primary: Daily Average Urine Capture Rate (Percentage) — 79.3; 34.3; 82.4; 24.2 Percentage of urine captured — p=0.076
Phase 2 N=373 A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants
Venous Thromboembolism
Primary: Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE) (REGN9933 vs Enoxaparin) — 17.2; 22.2 percentage of participants
N/A N=40 PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation Clinical Study
Aortoiliac Aneurysms · Iliac Aneurysms
Primary: Number of Patients With Freedom From Patency-related Intervention Defined as a Secondary Intervention to Treat a > 60 % Stenosis of the Internal Iliac Artery Associated…
Phase 4 N=620 Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age
Measles · Rubella · Rubella Syndrome, Congenital
Primary: Percent of Infants Who Were Seropositive After Immunization at 6 Months (Assessed at 9-month Visit) — 94; 94 percentage of infants
Phase 2 N=386 A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above
Respiratory Syncytial Virus Infections
Primary: RSV-A Serum Neutralizing Titers Expressed As Mean Geometric Increase (MGI) Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group — 1.34 Ratio